TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback